Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular risk management by blocking the endocannabinoid system.

P Bramlage1, I Mühlen, H Randeva

  • 1Institute for Clinical Pharmacology, Technical University, Dresden, Germany.

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association
|March 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter aortic valve replacement in heavily calcified aortic valve stenosis: a multicenter comparison.

Clinical research in cardiology : official journal of the German Cardiac Society·2025
Same author

A pilot study to assess the feasibility and uptake of MindDEC, a mindfulness-based self-management course for type 2 diabetes.

Complementary therapies in medicine·2024
Same author

The chance of transition: strategies for multidisciplinary collaboration.

Endocrine connections·2022
Same author

Audit of vaccination status of health-care workers who tested positive for SARS-CoV-2.

Journal of clinical virology plus·2022
Same author

Erythroderma (exfoliative dermatitis). Part 2: energy homeostasis and dietetic management strategies.

Clinical and experimental dermatology·2021
Same author

Healthcare staff perceptions towards influenza and potential COVID-19 vaccination in the 2020 pandemic context.

The Journal of hospital infection·2021

Blocking the cannabinoid receptor 1 (CB1) with drugs like Rimonabant shows promise for weight loss and improving cardiovascular health by targeting the body's natural endocannabinoid system.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Cardiovascular Medicine

Background:

  • The endocannabinoid system, involving endocannabinoids and cannabinoid receptor 1 (CB1), plays a role in regulating appetite and metabolism.
  • Stimulation of CB1 receptors increases food intake, while antagonists offer a potential therapeutic strategy for weight management.

Purpose of the Study:

  • To evaluate the efficacy of CB1 receptor blockade in reducing body weight and managing cardiovascular risk factors.
  • To explore the impact of CB1 receptor antagonists on metabolic parameters.

Main Methods:

  • Clinical studies involving Rimonabant, a CB1 receptor antagonist.
  • Assessment of body weight, waist circumference, HDL cholesterol, serum triglycerides, and insulin sensitivity.

Related Experiment Videos

Main Results:

  • Rimonabant treatment led to significant reductions in body weight and waist circumference.
  • Improvements in cardiovascular risk profile were observed, including increased HDL cholesterol, decreased triglycerides, and enhanced insulin sensitivity.

Conclusions:

  • CB1 receptor blockade represents a novel therapeutic approach for weight reduction and cardiovascular risk management.
  • Further research is needed to fully establish the role of these compounds in cardiovascular health.